Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAS1R3 | Q7RTX0 | 5/20 | 0.44 |
| ▸ | TAS1R1 | Q7RTX1 | 5/20 | 0.44 |
| ▸ | TAS1R2 | Q8TE23 | 2/20 | 0.44 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.43 |
| ▸ | DRD2 | P14416 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | CA1 | P00915 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
| ▸ | ACHE | P22303 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31690281 | 0.86 | DRD2 (0.43) | TAS1R3TAS1R1TAS1R2EPHX2DRD2 | |
| SCHEMBL18761357 | 0.81 | HTT (0.59) | TAS1R3TAS1R1TAS1R2KMT2ALMNA | |
| SCHEMBL29551628 | 0.81 | HTT (0.59) | TAS1R3TAS1R1TAS1R2KMT2ALMNA | |
| SCHEMBL5714269 | 0.81 | HTT (0.59) | TAS1R3TAS1R1TAS1R2KMT2ALMNA | |
| SCHEMBL22501388 | 0.80 | TAS1R3 (0.55) | TAS1R3TAS1R1TAS1R2CA1CA2 | |
| SCHEMBL28677537 | 0.80 | TAS1R3 (0.55) | TAS1R3TAS1R1TAS1R2CA1CA2 | |
| SCHEMBL20873493 | 0.80 | TAS1R3 (0.50) | TAS1R3TAS1R1TAS1R2KMT2ALMNA | |
| SCHEMBL29372292 | 0.78 | TAS1R3 (0.48) | TAS1R3TAS1R1TAS1R2KMT2ALMNA | |
| SCHEMBL26999632 | 0.76 | EPHX1 (0.57) | TAS1R3TAS1R1TAS1R2KMT2ALMNA | |
| SCHEMBL21183420 | 0.75 | LMNA (0.51) | TAS1R3TAS1R1TAS1R2EPHX2KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3464249-B1 | SUBSTITUTED CARBONUCLEOSIDE DERIVATIVES USEFUL AS ANTICANCER AGENTS | PFIZER (US) | 2021-08-11 | — | — | EP | disclosed |
| US-10709709-B2 | Substituted carbonucleoside derivatives useful as anticancer agents | PFIZER INC. (US) | 2020-07-14 | — | — | US | disclosed |
| US-20190111060-A1 | SUBSTITUTED CARBONUCLEOSIDE DERIVATIVES USEFUL AS ANTICANCER AGENTS | PFIZER INC. (US) | 2019-04-18 | — | — | US | disclosed |
| US-10220037-B2 | Substituted carbonucleoside derivatives useful as anticancer agents | PFIZER INC. (US) | 2019-03-05 | — | — | US | disclosed |
| US-10220037-B2 | Substituted carbonucleoside derivatives useful as anticancer agents | PFIZER INC. (US) | 2019-03-05 | — | — | US | disclosed |
| US-20170348313-A1 | SUBSTITUTED CARBONUCLEOSIDE DERIVATIVES USEFUL AS ANTICANCER AGENTS | PFIZER INC. (US) | 2017-12-07 | — | — | US | disclosed |
| US-20170348313-A1 | SUBSTITUTED CARBONUCLEOSIDE DERIVATIVES USEFUL AS ANTICANCER AGENTS | PFIZER INC. (US) | 2017-12-07 | — | — | US | disclosed |
| US-20170348313-A1 | SUBSTITUTED CARBONUCLEOSIDE DERIVATIVES USEFUL AS ANTICANCER AGENTS | PFIZER INC. (US) | 2017-12-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10709709-B2 | Substituted carbonucleoside derivatives useful as anticancer agents | DUT, NCL, TYMP | TAS1R3 4801/4885TAS1R1 4838/4885TAS1R2 4837/4885 |
| US-20170348313-A1 | SUBSTITUTED CARBONUCLEOSIDE DERIVATIVES USEFUL AS ANTICANCER AGENTS | DUT, NCL, TYMP | TAS1R3 4801/4885TAS1R1 4838/4885TAS1R2 4837/4885 |
| US-20190111060-A1 | SUBSTITUTED CARBONUCLEOSIDE DERIVATIVES USEFUL AS ANTICANCER AGENTS | DUT, NCL, TYMP | TAS1R3 4801/4885TAS1R1 4838/4885TAS1R2 4837/4885 |
| US-10220037-B2 | Substituted carbonucleoside derivatives useful as anticancer agents | DUT, NCL, TYMP | TAS1R3 4801/4885TAS1R1 4838/4885TAS1R2 4837/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.